8-K: Hempacco Faces Nasdaq Delisting Over Reporting and Meeting Deficiencies

Hempacco Co., Inc. has received a delisting notice from Nasdaq due to its failure to hold an annual shareholder meeting and file required financial reports.

Summary

• Hempacco Co., Inc. received a delisting notice from Nasdaq on July 1, 2024, because it did not hold an annual shareholder meeting within twelve months of its fiscal year end.
• The company also failed to file its Annual Report on Form 10-K for the year ended December 31, 2023, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.
• These failures put the company in non-compliance with Nasdaq's Listing Rules 5620(a) and 5250(c)(1).
• Hempacco intends to appeal the delisting decision and has requested a hearing before a Nasdaq Hearings Panel.
• The company is seeking an extended stay of the delisting while it works to file the overdue reports and hold the annual meeting.
• The company is focused on filing the Form 10-K prior to the hearing and the Form 10-Q shortly thereafter.
• The company is planning to hold an annual shareholder meeting shortly after the filings.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the company's failure to meet reporting deadlines. While the company is appealing, there are significant risks and uncertainties.

Positives

• Hempacco is actively appealing the delisting notice from Nasdaq.
• The company is focused on filing the overdue financial reports and holding the annual shareholder meeting.
• Hempacco is requesting an extended stay of the delisting, which could provide more time to regain compliance.

Negatives

• Hempacco has received a delisting notice from Nasdaq.
• The company failed to hold an annual shareholder meeting within the required timeframe.
• Hempacco is delinquent in filing its 2023 annual report (Form 10-K) and Q1 2024 quarterly report (Form 10-Q).
• There is a risk that Nasdaq may deny the company's appeal and delist its securities.

Risks

• There is a risk of further delays in the company's financial reporting.
• The ongoing review may identify errors or control deficiencies in the company's accounting practices.
• Identified control deficiencies could result in additional material weaknesses in the company's internal control over financial reporting.
• The company may be unable to regain compliance with Nasdaq's Listing Rules.
• Nasdaq may deny the company's appeal and delist its securities.

Future Outlook

The company is focused on filing the overdue financial reports and holding the annual shareholder meeting to regain compliance with Nasdaq listing rules. The company is seeking an extended stay of the delisting while it works to regain compliance.

Management Comments

• The company believes that it will satisfy the standards for the granting of such an extended stay.
• The company is focused on filing the Form 10-K prior to the hearing and the Form 10-Q shortly thereafter.

Industry Context

This announcement highlights the importance of timely financial reporting and adherence to exchange listing rules, which are critical for maintaining investor confidence and market access. Delisting can significantly impact a company's ability to raise capital and its overall valuation.

Comparison to Industry Standards

• Many companies listed on Nasdaq are required to file their annual reports (Form 10-K) within 90 days of their fiscal year end, and quarterly reports (Form 10-Q) within 45 days of the end of the quarter.
• Failure to meet these deadlines can result in non-compliance and potential delisting, as seen in this case with Hempacco.
• Other companies that have faced similar issues include those with internal control weaknesses or accounting irregularities, which can lead to delays in financial reporting.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the value of their investment.
• Employees may experience uncertainty due to the company's financial and compliance issues.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• Hempacco will request a hearing before a Nasdaq Hearings Panel.
• The company will seek an extended stay of the delisting.
• Hempacco will file its overdue Form 10-K and Form 10-Q.
• The company will hold an annual shareholder meeting.

Key Dates

Keywords

delisting, Nasdaq, Form 10-K, Form 10-Q, annual meeting, compliance, financial reporting, appeal, hearing, Hempacco